



MALIN

Malin Corporate Update

2 April 2019

Disclaimer

This document is personal to the recipient and has been prepared and issued by Malin Corporation plc (the "Company") incorporated and registered in Ireland under the Irish Companies Acts and is the responsibility of the Company. For the purposes of this notice, this presentation (the "Presentation") shall mean and include the slides, the oral presentation of the slides by the Company, hard copies of this document and any materials distributed at, or in connection with, that oral presentation. The slides are given in conjunction with an oral presentation and should not be taken out of context.

This Presentation does not constitute or form part of any offer for sale or solicitation of any offer to buy or subscribe for any securities nor shall it or any part of it form the basis of or be relied on in connection with, or act as any inducement to enter into, any contract or commitment whatsoever. No part of this Presentation, nor the fact of its distribution, should form the basis of, or be relied on in connection with, any contract or commitment or investment decision whatsoever. Any decision to purchase securities of the Company must be made solely on the basis of the information gained from the recipients' own investigations and analysis of the Company. The information in this Presentation is subject to update, revision, and/or amendment without notice. Reliance on this Presentation for the purpose of engaging in any investment activity may expose an individual to a significant risk of losing all of the property or other assets invested. This Presentation is not a prospectus (or prospectus equivalent document). This Presentation does not contain "Inside Information" as that term is defined in the Market Abuse Regulation.

This Presentation is strictly private and confidential, is being supplied to you solely for your information and may not be copied, further distributed, published or reproduced in whole or in part, or otherwise disclosed. Failure to comply with these restrictions may constitute a violation of applicable securities laws and/or a criminal offence. The content of this Presentation has not been approved

by Euronext Dublin. This Presentation is being communicated for information purposes only.

No representation or warranty, express or implied, is given by or on behalf of the Company or its investee companies or any of such persons' advisors, or any of their respective parent or subsidiary undertakings, the subsidiary undertakings of any such parent undertakings or any of the directors, officers, employees of such person as to the fairness, accuracy or completeness of the contents of this Presentation, for the opinions contained in this Presentation or for any other statement made or purported to be made by any of them, or on behalf of them and no responsibility or liability is accepted by any person for such information or opinions. No person has been authorised to give any information or make any representations other than those contained in this Presentation and, if given and/or made, such information or representations must not be relied upon as having been so authorised. The contents of this Presentation are not to be construed as legal, financial or tax advice. No liability is accepted for any such information or opinions by the Company or its investee companies, or any of their respective directors, members, officers, employees, agents or advisers.

Nothing in this Presentation shall be relied upon as a promise or representation in this respect, whether as to the past or the future. There is no obligation on any person to update this document, correct any inaccuracies which may become apparent or to publicly announce the result of any revision to the statements made herein except to the extent that they would be required to do so under applicable law or regulation. To the extent permitted by law, no responsibility or liability whatsoever is accepted by the Company or its investee companies or any of such persons' directors, officers, employees or affiliates or any other person for any loss howsoever arising, directly or indirectly, from any use of this Presentation or such information or opinions contained herein or otherwise arising in connection herewith. Except where otherwise indicated herein, the information

provided in this Presentation is based on matters as they exist as of the date of preparation and not as of any future date.

Certain statements included in this Presentation contain forward-looking information concerning the Company's and its investee companies' strategy, operations, financial performance or condition, outlook, growth opportunities or circumstances in the sectors or markets in which the Company and its investee companies operate. By their nature, forward-looking statements involve uncertainty because they depend on future circumstances, and relate to events, not all of which are within the Company's or its investee companies' control or can be predicted by the Company or by its investee companies. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, no assurance can be given that such expectations will prove to have been correct. Actual results could differ materially from those set out in the forward-looking statements. The forward-looking statements made in this Presentation relate only to events as of the date on which the statements are made. Nothing in this Presentation should be construed as a profit forecast and no part of these results constitutes, or shall be taken to constitute, an invitation or inducement to invest in the Company, and must not be relied upon in any way in connection with any investment decision. The Company expressly disclaim any obligation or undertaking to update or revise any forward-looking statement.

Opening Remarks

Ian Curley, Executive Chairman

Overview of Business Strategy & Progress



Delivery of value from refocused asset strategy



Commitment to return capital to shareholders following significant realisation events



Focus on clearly defined future investment strategy



Maintain efficient business structure with additional expertise within future investment focus areas



Sound independent governance & benchmarked remuneration structures

Focus on delivering value for shareholders

Operational & Financial Update

Darragh Lyons, Chief Business & Financial Officer

FY 2018 Financial Highlights



Malin's IFRS Consolidated Financial Statements include:

Full financial results of investee companies controlled by Malin

Malin's share of the losses of its associate investments

Fair value movements related to other assets held by Malin

Other investee company-related accounting charges and movements



Key 2018 Financial Highlights:

IPEV fair value of assets was €404 million

Cash of €43 million (28 March 2019: €34 million)

European Investment Bank debt of €55 million

Cash operating expenses: €8 million (2019 forecast: €7 million)

Fair value of Investee Companies

€404 million

IPEV guidelines are recognised as best practice in the valuation of private companies

Priority Assets


€298 million
IPEV fair value

Growth Potential Assets

€105 million
IPEV fair value

Legacy Assets

All other assets have been written off



Growth Potential Assets

3 Revenue Generative companies

24% of total IPEV fair value

2 Early-stage companies

2% of total IPEV fair value

2 Public asset equities


<1% of total IPEV fair value

What's in a Share?

Enterprise fair value is arrived at through our estimate of the fair value of our investee companies in accordance with IPEV guidelines adjusted for net debt

€8.57 per Malin share

Malin's share price at 31 December 2018 of €5.00 per share traded at a discount to management's estimate of enterprise fair value



Strong Clinical and Commercial Progress in Priority Assets in the past year



Progressed Ph.1 study of lead CAR-T program, P-BCMA-101, reporting positive data, having received RMAT designation from US FDA

Advanced late-stage pre-clinical development of other candidates



Progressed pivotal trial of lead candidate, IMCgp100, towards interim analysis

Completed co-dev / co-promo deal with Genentech for MAGE-A4 target (\$100m upfront)

Filed IND for MAGE-A4 target & dosed 1st patient in GSK-partnered, NYEso, trial

Appointed Bahija Jallal as CEO and David Berman as Head of R&D



Positive data from Ph.1 study of lead, KY1005 anti-OX40L, & initiated Ph.2a study

Filed IND for KY1044 anti-ICOS candidate

Continued to expand & advance discovery & preclinical antibody pipeline



Completed structured sale of lead asset, VT-1161, to NovaQuest. Potential of significant & recurring cash flows from milestones and sales royalties.

Key Investee Catalysts within the next year



Poseida

Complete Phase 1 trial of P-BCMA-101

Begin registrational clinical trial for P-BCMA-101

File IND for prostate cancer target (P-PSMA-101) and begin Phase 1 trials

File IND for multiple solid tumour indication (P-MUC1C-101)

File IND for allogeneic product candidate (P-BCMA-ALLO1)



Immunocore

Interim analysis of data of IMCgp100 in metastatic uveal melanoma

Potential to file BLA for IMCgp100

Dose 1st patient in Phase 1 trials for MAGE-A4 target (Genentech collaboration)

Additional IND filings

Additional partnerships



Kymab

Phase 2a data in anti-OX40L atopic dermatitis indication (KY1005)

Expand KY1005 into other anti-inflammatory indications (acute Graft v Host Disease)

RP2D for anti-ICOS agonist (advanced solid tumours) indication (KY1044)



Other Assets

Viamet antifungal interest (VT-1161) to advance through Phase 3 trials (funded by NovaQuest)

Altan NDA approval for IV paracetamol

3D4Medical revenue growth

Xenex to file 510(k) application for next-generation robot

Outlook



Several assets with important milestones in the year ahead, which have the potential to create significant value for shareholders



Focus on delivery of this value and committed to returning capital to shareholders



Focus on clearly defined future investment focus area



Cash operating expenses at a run-rate of €7 million (<2% of asset fair value)



Efficient business structure with additional expertise within future investment focus area

Q&A Session

Ian Curley & Darragh Lyons

How to find out more

Malin Contact



Jessica Bergin

Director of Investor Relations

+353 1 901-5700

investorrelations@malinplc.com



MALIN

Thank you

malinplc.com